Low Density Lipoprotein Hemoperfusion by Direct Adsorption of Lipoproteins from Whole Blood (DALI Apheresis): Clinical Experience from a Single Center

• Published in: Therapeutic apheresis 1999-08, Vol.3 (3), p.209-213
• Main Authors: Bosch, T, Lennertz, A, Kordes, B, Samtleben, W
• Format: Article
• Language: English
• Subjects: Adsorption; Angiotensin converting enzyme inhibitors; Direct adsorption of lipoprotein; Female; Hemoperfusion - methods; Humans; Hypercholesterolemia - therapy; Lipoprotein (a); Lipoprotein(a) - isolation & purification; Lipoproteins, LDL - isolation & purification; Low density lipoprotein; Low density lipoprotein apheresis; Male; Middle Aged; Treatment Outcome
• ISSN: 1091-6660; 1526-0968
• DOI: 10.1046/j.1526-0968.1999.00162.x

The elimination of low density lipoprotein (LDL) and lipoprotein (a) (Lp[a]) by conventional LDL apheresis techniques can only be achieved in a cell‐free medium and thus requires the initial separation of plasma from the blood cells. The present paper describes the first LDL hemoperfusion system which is able to adsorb LDL and Lp(a) directly from whole blood. This simplifies the procedure substantially. The adsorber consists of polyacrylate ligands linked to a modified polyacrylamide matrix. These negatively charged polyacrylate ligands interact with the positively charged apoprotein B moiety of LDL and Lp(a), which results in selective adsorption of these lipoproteins onto the column. Three hypercholesterolemic patients suffering from overt atherosclerotic complications were treated weekly by direct adsorption of lipoproteins (DALI) (n = 20 sessions each). All patients were on the highest tolerated dose of cholesterol synthesis enzyme (CSE) inhibitors. About 1.3 patient blood volumes were treated per session. The anticoagulation was performed with acid citrate dextrose (ACD‐A). The following acute reductions were achieved: LDL: 66%; Lp(a): 63%; and triglycerides: 29%. High density lipoprotein (HDL) (− 13%) and fibrinogen (−16%) were not substantially reduced. The sessions were essentially uneventful. Due to a low ACD‐A infusion rate, no hypocalcemic episodes were registered. One patient on enalapril was treated without complications when this angiotensin converting enzyme (ACE) inhibitor was withdrawn 2 days prior to apheresis. In summary, in our hands, DALI apheresis proved to be a simple, safe, and efficient method of lipid apheresis in hypercholesterolemic patients refractory to conservative lipid lowering therapy.